HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lasley, R. D. Articles by Smart, E. J. Search for Related Content PubMed PubMed Citation Articles by Lasley, R. D. Articles by Smart, E. J. Social Bookmarking                      What's this?

J Biol Chem, Vol. 275, Issue 6, 4417-4421, February 11, 2000

Activated Cardiac Adenosine A₁ Receptors Translocate Out of Caveolae^*

Robert D. Lasley, Prakash Narayan, Annette Uittenbogaard^§, and Eric J. Smart^§¶

From the Departments of ^§ Physiology and  Surgery, University of Kentucky Medical School, Lexington, Kentucky 40536

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

The cardiac affects of the purine nucleoside, adenosine, are well known. Adenosine increases coronary blood flow, exerts direct negative chronotropic and dromotropic effects, and exerts indirect anti-adrenergic effects. These effects of adenosine are mediated via the activation of specific G protein-coupled receptors. There is increasing evidence that caveolae play a role in the compartmentalization of receptors and second messengers in the vicinity of the plasma membrane. Several reports demonstrate that G protein-coupled receptors redistribute to caveolae in response to receptor occupation. In this study, we tested the hypothesis that adenosine A₁ receptors would translocate to caveolae in the presence of agonists. Surprisingly, in unstimulated rat cardiac ventricular myocytes, 67 ± 5% of adenosine A₁ receptors were isolated with caveolae. However, incubation with the adenosine A₁ receptor agonist 2-chlorocyclopentyladenosine induced the rapid translocation of the A₁ receptors from caveolae into non-caveolae plasma membrane, an effect that was blocked by the adenosine A₁ receptor antagonist, 8-cyclopentyl-1,3-dipropylxanthine. An adenosine A_2a receptor agonist did not alter the localization of A₁ receptors to caveolae. These data suggest that the translocation of A₁ receptors out of caveolae and away from compartmentalized signaling molecules may explain why activation of ventricular myocyte A₁ receptors are associated with few direct effects.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Adenosine has multiple and profound effects on cardiac function. Adenosine increases coronary blood flow and exerts direct negative chronotropic and dromotropic effects (1). There is also significant evidence that adenosine reduces both reversible and irreversible myocardial ischemic-reperfusion injury (2). The cardiac effects of adenosine are mediated by the activation of specific extracellular adenosine receptor subtypes, A₁, A_2a, and A₃, located on vascular smooth muscle, coronary endothelial cells, and cardiac myocytes (1). The adenosine A₁ receptor subtype is localized primarily on cardiac myocytes (1).

The adenosine A₁ receptor is a 36-kDa, seven-transmembrane domain protein localized to the sarcolemma (3). Agonist binding induces a conformational change in the receptor, which facilitates its interaction with an inhibitory guanine nucleotide-binding protein (G_i) (3). With the exception of the ferret, adenosine A₁ receptor occupation does not significantly alter contractility, intracellular calcium, or cAMP concentration in normal mammalian ventricular myocardium (4). However, A₁ receptor occupation does reduce -adrenergic receptor-induced increases in all of the above parameters. Although the anti-adrenergic effect of adenosine is well studied, evidence of other signal transduction mechanisms mediated by adenosine A₁ receptor occupation in ventricular myocardium is lacking. The fact that other receptors in ventricular myocytes, which presumably couple to the same G_i protein, produce direct effects (5-8) raises the question of why adenosine A₁ receptor activation is associated with so few effects. One explanation for the lack of direct adenosine A₁ receptor effects may be the relatively low receptor density in ventricular myocardium compared with atrial tissue (9). Another possibility is that the receptor is inefficiently coupled to G_i proteins and second messengers. Coupling efficiency may be due, in part, to the grouping of receptors and second messengers in microdomains for rapid and selective activation or deactivation of intracellular signaling mechanisms.

Caveolae are cholesterol/sphingomyelin-rich plasma membrane microdomains that have been shown to serve as a scaffold for receptors and second messengers (10). Caveolae are present in most cell types and are abundant in cardiomyocytes (11). There are several reports that G protein-coupled receptors redistribute to caveolae in response to receptor occupation (11-13). In addition, other studies have documented that specific second messenger systems, including heterotrimeric G proteins, are concentrated in caveolae (for review, see Ref. 10). Although the role of caveolae in cardiac signal transduction has not been well studied, it has been reported that muscarinic M₂ cholinergic receptors in rat ventricular cardiomyocytes localize to caveolae after agonist stimulation (11).

Because adenosine and acetylcholine exert similar effects in ventricular myocardium (14), we hypothesized that stimulation of adenosine A₁ receptors would promote translocation of the receptors into caveolae. Surprisingly, we found that in rat ventricular cardiomyocytes, adenosine A₁ receptors were associated with caveolae in unstimulated cells, whereas activation of the adenosine A₁ receptors induced the receptors to translocate out of caveolae.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Materials-- Mouse IgGs directed against caveolin-3, clathrin, and eNOS were obtained from Transduction Laboratories (Lexington, KY). Rabbit IgGs directed against the adenosine A₁ receptor were supplied by Alpha Diagnostic International (San Antonio, TX) and Chemicon International (Temecula, CA). Mouse IgG directed against the human transferrin receptor was supplied by Zymed Laboratories Inc. (San Francisco, CA). Horseradish peroxidase-conjugated IgGs were supplied by Cappel (West Chester, PA). Super Signal^® chemiluminescent substrate was purchased from Pierce. The cholesterol determination kit was from Wako (Richmond, VA). [³H]Acetate (5.21 Ci/mmol) were supplied by Amersham Pharmacia Biotech. Adenosine receptor agonists (CCPA,¹ CGS 21680) and antagonist (DPCPX) were obtained from Research Biochemicals International (Natick, MA). Adenosine deaminase and dimethyl sulfoxide (Me₂SO) were obtained from Sigma.

Isolation of Rat Ventricular Cardiomyocytes-- All animals in this study received humane care according to the guidelines set forth by the National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals prepared by the National Academy of Sciences and prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication 86-23, revised 1996).

Ventricular myocytes were dissociated from adult, male Sprague-Dawley rats (350-400 g) using collagenase and hyaluronidase as described previously (15). The resulting cell suspension was washed twice with enzyme-free buffer, and suspended in normal HEPES buffer (1.0 mM CaCl₂, pH = 7.4) to a final concentration of ~1 mg/ml. Typically, over 70% of the cells were rod-shaped, trypan blue-excluding ventricular myocytes.

Isolation of Caveolae-- Caveolae were isolated as described previously (16). Ten to 15 µg of purified caveolae were isolated from three rat heart preparations with this method.

Enzyme Assays-- Alkaline phosphatase was measured by the method of Engstrom (17). Galactosyltransferase and NADPH-cytochrome c reductase were assayed using methods adapted from Graham (18). Lactate dehydrogenase was measured with a standard kit from Sigma.

Cholesterol Mass Measurements-- The mass of cholesterol was determined as described previously (19).

SDS-PAGE, Immunoblotting, and Immunoprecipitations-- Cellular fractions were processed as described previously (16).

Treatment Protocols-- Three groups (n = 2-3 experiments/group) of cells were studied. To provide enough protein sample for the fractionation of cell lysates, the cardiomyocyte yield from three hearts was combined in a single experiment. All myocyte suspensions were performed in the presence of adenosine deaminase (2 units/ml) to degrade endogenous adenosine. Control myocytes were suspended at room temperature in 7 ml of HEPES buffer (~3-4 mg of protein/ml) with periodic mixing. A second group of myocytes was incubated with the adenosine A₁ receptor agonist 2-chloro-N⁶-cyclopentyladenosine (CCPA, 200 nM) for 15 min. The suspension was then centrifuged (1000 × g), and the pellet was washed three times with normal HEPES buffer (10 ml). After the final wash, the myocyte pellet was processed to isolate caveolae as described above. Group 3 myocytes were initially pretreated with the adenosine A₁ receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, 200 nM) for 5 min prior to the addition of CCPA (200 nM). One additional experiment was performed in which myocytes were incubated with the adenosine A_2a receptor agonist 2-p-(2-carboxyethyl)- phenethylamino-5'-N-ethylcarboxyamidoadenosine (CGS 21680, 100 nM) as described for CCPA.

Immunoelectron Microscopy-- Immunogold localization of caveolin-3 (20 nm gold) and A₁ receptors (5 nm gold) was performed using whole mount plasma membrane preparations as described previously (20).

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Isolation of Caveolae from Rat Ventricular Myocytes-- We defined the presence of caveola in ventricular myocytes by an established isolation procedure (16). In brief, ventricular myocytes were lysed and a postnuclear supernatant generated. The postnuclear supernatants were separated into cytosol, plasma membrane, and intracellular membrane (endoplasmic reticulum, Golgi, etc.) fractions by centrifugation in Percoll. The plasma membranes were then sonicated and fractionated by density gradient centrifugation to isolate caveolae. Similar to other cell type studies, the caveola fraction from ventricular myocytes contained less than 0.4% of the protein found in the initial postnuclear supernatant fraction (Table I).

The most probable contaminates of the plasma membrane and caveola fractions are the endoplasmic reticulum and Golgi. Therefore, we measured the amount of NADPH-cytochrome reductase (endoplasmic reticulum) and galactosyltransferase (Golgi) activity in each of the subcellular fractions (Table I). The majority of the activities were associated with the intracellular membranes. The plasma membrane contained less than 2% of the total postnuclear supernatant activities, and the caveola fraction did not contain any detectable NADPH cytochrome reductase or galactosyltransferase activity.

To ensure that the caveola fraction was not contaminated with other plasma membrane domains, 5 µg (Fig. 1A) or 3% (Fig. 1B) of each subcellular fraction was resolved by SDS-PAGE and immunoblotted for various caveola and non-caveola proteins. The equal protein loads in Fig. 1A illustrate the relative enrichment of each protein in the caveola fraction, whereas the proportional protein loads in Fig. 1B illustrate total protein distribution. Caveolin-3, a marker for muscle caveolae, was highly enriched in the caveola fraction. In addition, eNOS, which has been shown to directly interact with caveolin (21), was also enriched in the caveola fraction. The non-caveola proteins, clathrin and transferrin, were excluded from the caveola fraction. The yield of caveolin-3 and eNOS in the caveola fraction was determined by immunoblot analysis in the linear range of detection (data not shown). The estimated yield, with respect to the plasma membrane fraction, of caveolin-3 was 61 ± 6% and eNOS was 69 ± 8%.

View larger version (70K): [in this window] [in a new window]   Fig. 1.   Characterization of rat ventricular cardiomyocyte caveolae. A, 5 µg of protein from each subcellular fraction was resolved by SDS-PAGE and immunoblotted for caveolin-3 and eNOS (caveola markers) and transferrin receptor and clathrin (non-caveola markers). B, equal proportions of each subcellular fraction (3%) were resolved by SDS-PAGE and immunoblotted as described above. PNS, postnuclear supernatant (96 µg); CYTO, cytosol (45 µg); IM, total intracellular membranes (43 µg); PM, total plasma membrane (6 µg); CM, caveola membrane (0.3 µg). The immunoblots were developed by the method of chemiluminescence. The caveolin-3 immunoblot was exposed for 10 s and the eNOS, transferrin receptor (TR), and clathrin immunoblots were exposed for 3 min. Representative data from four independent experiments are shown.

Caveolae are highly enriched in cholesterol (16). To further characterize the myocyte caveola fraction, we used an enzymatic kit to determine the mass of cholesterol associated with each fraction. Fig. 2 demonstrates that the caveola fraction, which contained 24 µg of cholesterol, was 7.4-fold more enriched in cholesterol than the plasma membrane fraction, which contained 79 µg of cholesterol.

View larger version (11K): [in this window] [in a new window]   Fig. 2.   Myocyte caveolae are highly enriched in cholesterol. The relative enrichment of cholesterol in each subcellular fraction (µg of cholesterol/mg of fraction protein) was determined using a commercially available kit (see "Experimental Procedures"). PNS, postnuclear supernatant; CYTO, cytosol; IM, total intracellular membranes; PM, total plasma membrane; CM, caveola membrane. The data are from three independent experiments, mean ± S.E., n = 3.

Subcellular Localization of Adenosine A₁ Receptors-- The subcellular distribution of A₁ receptors under basal conditions was determined in ventricular myocytes incubated in HEPES buffer supplemented with adenosine deaminase. Three percent of each subcellular fraction was analyzed for the presence of A₁ receptors by SDS-PAGE and immunoblotting. Under these conditions, A₁ receptors were highly concentrated (67 ± 5% with respect to the plasma membrane) in the caveola fraction (Fig. 3A, Buffer). Similar results were obtained in two other groups of control myocytes.

View larger version (40K): [in this window] [in a new window]   Fig. 3.   CCPA induces the translocation of adenosine A1 receptors out of caveolae. A, ventricular cardiomyocytes were treated for 15 min with buffer, 200 nM CCPA, 200 nM CCPA + 200 nM DPCPX, or 100 nM CGS. The cells were then washed and processed to isolate caveola membranes. Equal proportions of each subcellular fraction (3%) were resolved by SDS-PAGE and immunoblotted for A1 receptor. PNS, postnuclear supernatant (101 µg); CYTO, cytosol (53 µg); IM, total intracellular membranes (41 µg); PM, total plasma membrane (7 µg); CM, caveola membrane (0.24 µg). The immunoblots were developed by the method of chemiluminescence (10-min exposures). A1 receptor was identified as a 37-kDa cross-reactive band. B, to confirm the fidelity of the caveola isolations in A, equal proportions of each subcellular fraction (3%) were resolved by SDS-PAGE and immunoblotted for caveolin-3, eNOS, transferrin receptor, and clathrin. Shown are data for cells treated with CCPA. Control immunoblots for the other treatments were similar (data not shown). Representative data from four independent experiments are shown.

We next determined the subcellular localization of A₁ receptors after incubating myocytes with the A₁ receptor agonist CCPA. Treatment with CCPA caused the quantitative removal of A₁ receptors out of the caveola fraction (Fig. 3A, CCPA). Similar results were obtained when this treatment was repeated in additional myocytes. Quantification of the immunoreactive bands demonstrated that greater than 90% of the signal originally detected in the caveola fraction was now detected in the plasma membrane fraction (data not shown). To verify that this caveola to plasma membrane translocation was selective for A₁ receptors, two additional protocols were performed. In the first, pretreatment of myocytes with the A₁ receptor antagonist DPCPX prior to addition of CCPA prevented the redistribution of the receptor (Fig. 3A, CCPA + DPCPX). Finally, treatment of cells with the A_2a agonist CGS 21680 did not affect the caveola localization of the A₁ receptor (Fig. 3A, CGS). Immunoblots for caveola and non-caveola marker proteins demonstrated that CCPA treatment did not alter the yield or purity of caveolae (Fig. 3B).

Recently, Stan et al. (22) suggested that subcellular fractionation methods to isolate caveolae are contaminated with vesicles with similar biophysical properties as caveolae. Therefore, to verify that A₁ receptors are associated with caveolae, we used caveolin-3 IgG to immunoprecipitate caveola membranes from isolated caveolae. Isolated ventricular myocytes were incubated in control or CCPA-supplemented HEPES buffer for 15 min, then processed to immunoprecipitate caveolae with caveolin-3 IgG. The precipitated material and the remaining supernatants were resolved by SDS-PAGE and immunoblotted with IgGs for eNOS, A₁ receptor, and caveolin-3. Caveolin-3 co-immunoprecipitated eNOS and the A₁ receptor from caveolae isolated from cells treated with buffer (Fig. 4, Buffer). However, caveolin-3 only co-immunoprecipitated eNOS from caveolae isolated from cells treated with CCPA (Fig. 4, CCPA). Approximately 10% of caveolin-3, eNOS, and A₁ receptor was not precipitated with caveolin-3 IgG.

View larger version (62K): [in this window] [in a new window]   Fig. 4.   CCPA prevents the co-immunoprecipitation of adenosine A1 receptors with caveolin-3. Ventricular cardiomyocytes were incubated in control buffer or treated for 15 min with buffer containing CCPA (200 nM) at 37 °C. The cells were then processed to isolate caveola membranes. IgG directed against caveolin-3 (2 µg/ml) was used to immunoprecipitate caveolae from the caveola enriched subcellular fraction. The entire precipitate and the entire supernatant was resolved by SDS-PAGE and immunoblotted for eNOS, A1 receptor, and caveolin-3. The immunoblots were developed by the method of chemiluminescence (4-min exposures). Representative data from three independent experiments are shown. PEL, pellet; SUP, supernatant.

We have shown by subfractionation and immunoprecipitation that A₁ receptors are localized to caveolae. To confirm these findings in an independent manner, A₁ receptors were localized by immunoelectron microscopy. Cells were treated with buffer (Fig. 5A) or CCPA (Fig. 5B) as described above. The membranes were then processed to localize caveolin-3 (arrowheads) and A₁ receptors (arrows). Caveolin-3 and A₁ receptors were found over small invaginations on the membrane surface that had the characteristic appearance of caveolae in buffer-treated cells. However, after CCPA treatment, only caveolin-3 was associated with these small invaginations.

View larger version (109K): [in this window] [in a new window]   Fig. 5.   Localization of caveolin-3 and A1 receptors in plasma membranes by immunoelectron microscopy. Immunogold labeling was performed using monoclonal anti-caveolin-3 IgG and polyclonal anti-A1 receptor IgG. Caveolin-3 staining is marked with arrowheads, and A1 receptor staining is marked with arrows. Bar = 0.2 µm.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

This is the first report of adenosine receptor association with caveolae. Under basal conditions, ventricular myocyte A₁ receptors were localized primarily in caveolae. However, after agonist (CCPA) binding, A₁ receptors translocated from the caveolae to the plasma membrane fraction. This effect was blocked by prior treatment with the selective A₁ receptor antagonist DPCPX, indicating that this phenomenon is agonist-specific. This unique pattern of receptor localization may explain, in part, the lack of direct effects of A₁ receptor in ventricular myocytes.

The A₁ receptor is a member of the family of G protein-coupled receptors containing a seven-transmembrane-spanning domain. There are several reports that similar G protein-coupled receptors, e.g. angiotensin II (12), bradykinin B₂ (13), and endothelin A (23), and muscarinic receptors (13) are present in caveolae. However, the present results indicate that, in contrast to these receptors, the A₁ receptor translocates out of, rather than into, caveolae with receptor activation. There are at least two differences between ventricular myocyte A₁ receptors and these other G protein-coupled receptors, which may explain this unique relationship of A₁ receptors with caveolae. First, angiotensin II, bradykinin, and endothelin have been reported to increase intracellular calcium and exert direct inotropic effects in ventricular myocytes (5-7). In contrast, A₁ receptor occupation is not associated with these effects (4). Another difference is the phenomenon of receptor desensitization. Angiotensin II, bradykinin B₂, and endothelin A receptors all desensitize within minutes of receptor activation (24-26). In fact, it has been hypothesized that receptor movement into caveolae may play a role in this phenomenon (27). Cardiac A₁ receptors desensitize only after several hours to days of continuous agonist treatment (28). It should be noted that movement out of caveolae is also associated with desensitization because agonist-induced translocation of epidermal growth factor receptor out of caveolae is associated with rapid desensitization (29).

Our observation of A₁ receptor translocation from caveolae to sarcolemma after agonist treatment is the opposite of that reported for the ventricular myocyte muscarinic M₂ receptor (11). This is surprising, given the fact that A₁ and muscarinic M₂ receptors exert a nearly identical pertussis toxin-sensitive anti-adrenergic effect in ventricular myocytes. However, muscarinic receptors have several properties unique from A₁ receptors, which may explain these different associations with caveolae. The muscarinic agonist carbachol, at doses similar to that used by Feron et al. (11), increases inositol phosphate turnover, intracellular Ca²⁺, and contractility in ventricular myocytes (5). In addition, it appears that muscarinic M₂ receptors may exert direct effects in ventricular myocytes via coupling to eNOS (11). Similar to the observations of Feron et al. (11), we observed in the present study that eNOS is localized in caveolae. Finally, it has been reported that muscarinic M₂ receptors can be desensitized with brief agonist exposure (30).

The A₁ receptor antibody used in this study (Chemicon International) was raised against the third extracellular domain of the rat adenosine A₁ receptor gene (amino acids 163-176). In addition to the 36-kDa band (the A₁ receptor is a 36-kDa protein), the antibody also cross-reacted with a 74-kDa band. Ciruela et al. (31) also observed a 74-kDa band in several tissues (brain, kidney, lung) in several species (rat, pig, lamb) using a rabbit polyclonal antibody raised against the same peptide sequence of the rat A₁ receptor. They reported that this band was converted to a 39-kDa form after agonist binding. We observed similar results in the present study, although agonist binding did not convert all of the higher molecular weight band to the lower molecular weight form. The mechanistic explanation for this observation is not known. Identical results were obtained with an Alpha Diagnostic International antibody generated against the same epitope (data not shown).

Several lines of evidence support the hypothesis that A₁ receptor movement between caveolae and sarcolemma is dependent on occupation of the receptor by an A₁ agonist. First, all studies were performed in the presence of adenosine deaminase to degrade endogenously released adenosine. The subsequent addition of the A₁ receptor agonist CCPA, which is relatively selective for A₁ receptors, resulted in the movement of the receptor from caveolae to sarcolemmal membranes. At the concentration used in the present study, there is no evidence that CCPA activates cardiac myocyte A_2a or A₃ receptors. In addition, the A_2a agonist CGS 21680 did not induce A₁ receptor translocation from caveolae. Finally, DPCPX, which is a highly selective adenosine A₁ receptor antagonist (32), completely blocked the effects of CCPA.

Since this is the first report of the localization of the A₁ receptor in caveolae, it is not known whether A₁ receptor translocation out of caveolae activates or terminates signaling. There are reports that inhibitory G protein subunits are localized in caveolae (33), and cardiac A₁ receptors couple primarily to G_i subunits (34). Two components of the only known pathway that A₁ receptor activation modulates in ventricular myocardium, -adrenergic receptors and adenylyl cyclase, have been reported to be localized in light vesicular fractions which may be caveolae (35, 36). Furthermore, cardiac adenylyl cyclase can be inhibited in vitro by the caveolin-3 scaffolding domain peptide (37). Therefore, the location of A₁ receptors is likely to significantly influence the ability of the receptors to couple to downstream signaling events. It has recently been reported that stimulation of rat cardiac myocytes with endothelin is associated with the recruitment of PKC- and - isoforms to the caveolae fraction (38). Henry et al. (39) previously reported that A₁ receptor stimulation of ventricular myocytes induced a transient cytosol to membrane translocation of PKC-. Since endothelin, but not A₁, receptor stimulation is associated with direct effects in myocytes, it is possible that A₁ receptor stimulation may recruit PKC-  out of caveolae, where PKC signaling may be physiologically important.

In summary, we have demonstrated that, in contrast to other G protein-coupled receptors, A₁ receptors translocate out of caveolae with agonist binding. The molecular consequences of this translocation are not known. Future studies will elucidate the relationship between A₁ receptors, caveolae, and signal transduction.

	FOOTNOTES

^* This work was supported by Grant-in-aid 96015370 from the American Heart Association (to R. D. L.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^¶ To whom correspondence should be addressed: Dept. of Physiology, University of Kentucky, 800 Rose St., MS 508 C, Lexington, KY 40536. Tel.: 606-323-6412; Fax: 606-323-1070; E-mail: ejsmart@pop.uky.edu.

	ABBREVIATIONS

The abbreviations used are: CCPA, 2-chloro-N⁶-cyclopentyladenosine; PAGE, polyacrylamide gel electrophoresis; eNOS, endothelial nitric-oxide synthase; PKC, protein kinase C; CGS, 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxyamidoadenosine; DPCPX, 8-cyclopentyl-1,3-dipropylxanthine.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				N. M. Urs, A. P. Kowalczyk, and H. Radhakrishna Different Mechanisms Regulate Lysophosphatidic Acid (LPA)-dependent Versus Phorbol Ester-dependent Internalization of the LPA1 Receptor J. Biol. Chem., February 29, 2008; 283(9): 5249 - 5257. [Abstract] [Full Text] [PDF]

				S. Somara, R. R. Gilmont, J. R. Martens, and K. N. Bitar Ectopic expression of caveolin-1 restores physiological contractile response of aged colonic smooth muscle Am J Physiol Gastrointest Liver Physiol, July 1, 2007; 293(1): G240 - G249. [Abstract] [Full Text] [PDF]

				H. H. Patel, Y. M. Tsutsumi, B. P. Head, I. R. Niesman, M. Jennings, Y. Horikawa, D. Huang, A. L. Moreno, P. M. Patel, P. A. Insel, et al. Mechanisms of cardiac protection from ischemia/reperfusion injury: a role for caveolae and caveolin-1 FASEB J, May 1, 2007; 21(7): 1565 - 1574. [Abstract] [Full Text] [PDF]

				P. Savi, J.-L. Zachayus, N. Delesque-Touchard, C. Labouret, C. Herve, M.-F. Uzabiaga, J.-M. Pereillo, J.-M. Culouscou, F. Bono, P. Ferrara, et al. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts PNAS, July 18, 2006; 103(29): 11069 - 11074. [Abstract] [Full Text] [PDF]

				R. C. Balijepalli, J. D. Foell, D. D. Hall, J. W. Hell, and T. J. Kamp From the Cover: Localization of cardiac L-type Ca2+ channels to a caveolar macromolecular signaling complex is required for beta2-adrenergic regulation PNAS, May 9, 2006; 103(19): 7500 - 7505. [Abstract] [Full Text] [PDF]

				Y. Fu, X. Huang, H. Zhong, R. M. Mortensen, L. G. D'Alecy, and R. R. Neubig Endogenous RGS Proteins and G{alpha} Subtypes Differentially Control Muscarinic and Adenosine-Mediated Chronotropic Effects Circ. Res., March 17, 2006; 98(5): 659 - 666. [Abstract] [Full Text] [PDF]

				O. Feron and J.-L. Balligand Caveolins and the regulation of endothelial nitric oxide synthase in the heart Cardiovasc Res, March 1, 2006; 69(4): 788 - 797. [Abstract] [Full Text] [PDF]

				D. R. L. Scriven, A. Klimek, P. Asghari, K. Bellve, and E. D. W. Moore Caveolin-3 Is Adjacent to a Group of Extradyadic Ryanodine Receptors Biophys. J., September 1, 2005; 89(3): 1893 - 1901. [Abstract] [Full Text] [PDF]

				J. L. Macdonald and L. J. Pike A simplified method for the preparation of detergent-free lipid rafts J. Lipid Res., May 1, 2005; 46(5): 1061 - 1067. [Abstract] [Full Text] [PDF]

				C. Ballard-Croft, G. Kristo, Y. Yoshimura, E. Reid, B. J. Keith, R. M. Mentzer Jr., and R. D. Lasley Acute adenosine preconditioning is mediated by p38 MAPK activation in discrete subcellular compartments Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1359 - H1366. [Abstract] [Full Text] [PDF]

				M. Xue, C. M. Vines, T. Buranda, D. F. Cimino, T. A. Bennett, and E. R. Prossnitz N-Formyl Peptide Receptors Cluster in an Active Raft-associated State Prior to Phosphorylation J. Biol. Chem., October 22, 2004; 279(43): 45175 - 45184. [Abstract] [Full Text] [PDF]

				B. Aravamudan, D. Volonte, R. Ramani, E. Gursoy, M. P. Lisanti, B. London, and F. Galbiati Transgenic overexpression of caveolin-3 in the heart induces a cardiomyopathic phenotype Hum. Mol. Genet., November 1, 2003; 12(21): 2777 - 2788. [Abstract] [Full Text] [PDF]

				J. P. Headrick, B. Hack, and K. J. Ashton Acute adenosinergic cardioprotection in ischemic-reperfused hearts Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H1797 - H1818. [Abstract] [Full Text] [PDF]

				S. M. Joseph, M. R. Buchakjian, and G. R. Dubyak Colocalization of ATP Release Sites and Ecto-ATPase Activity at the Extracellular Surface of Human Astrocytes J. Biol. Chem., June 20, 2003; 278(26): 23331 - 23342. [Abstract] [Full Text] [PDF]

				L. Liu, K. Mohammadi, B. Aynafshar, H. Wang, D. Li, J. Liu, A. V. Ivanov, Z. Xie, and A. Askari Role of caveolae in signal-transducing function of cardiac Na+/K+-ATPase Am J Physiol Cell Physiol, June 1, 2003; 284(6): C1550 - C1560. [Abstract] [Full Text] [PDF]

				L. J. Pike Lipid rafts: bringing order to chaos J. Lipid Res., April 1, 2003; 44(4): 655 - 667. [Abstract] [Full Text] [PDF]

				S. E. Woodman, D. S. Park, A. W. Cohen, M. W.-C. Cheung, M. Chandra, J. Shirani, B. Tang, L. A. Jelicks, R. N. Kitsis, G. J. Christ, et al. Caveolin-3 Knock-out Mice Develop a Progressive Cardiomyopathy and Show Hyperactivation of the p42/44 MAPK Cascade J. Biol. Chem., October 4, 2002; 277(41): 38988 - 38997. [Abstract] [Full Text] [PDF]

				S. A. Masino, L. Diao, P. Illes, N. R. Zahniser, G. A. Larson, B. Johansson, B. B. Fredholm, and T. V. Dunwiddie Modulation of Hippocampal Glutamatergic Transmission by ATP Is Dependent on Adenosine A1 Receptors J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 356 - 363. [Abstract] [Full Text] [PDF]

				B. Razani, S. E. Woodman, and M. P. Lisanti Caveolae: From Cell Biology to Animal Physiology Pharmacol. Rev., September 1, 2002; 54(3): 431 - 467. [Abstract] [Full Text] [PDF]

				S. V. Sitaraman, L. Wang, M. Wong, M. Bruewer, M. Hobert, C-H. Yun, D. Merlin, and J. L. Madara The Adenosine 2b Receptor Is Recruited to the Plasma Membrane and Associates with E3KARP and Ezrin upon Agonist Stimulation J. Biol. Chem., August 30, 2002; 277(36): 33188 - 33195. [Abstract] [Full Text] [PDF]

J. F. Kincer, A. Uittenbogaard, J. Dressman, T. M. Guerin, M. Febbraio, L. Guo, and E. J. Smart Hypercholesterolemia Promotes a CD36-dependent and Endothelial Nitric-oxide Synthase-mediated Vascular Dysfunction J. Biol. Chem., June 21, 2002; 277(26): 23525 - 23533. [Abstract] [Full Text] [PDF]